On May 10, 2023, researchers from Memorial Sloan Kettering Cancer Center published results from a phase 1 clinical trial of the use of Messenger RNA vaccines (used to prevent or lessen the impact of COVID-19 infection) in treating patients with pancreatic cancer following resection of their tumors. Post-surgical treatment that included the vaccines triggered a robust immune response that delayed the recurrence of patients’ pancreatic cancer. The next steps include conducting a much larger and randomized clinical trial across multiple locations beginning summer 2023.